R&D channel feed

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

6 years ago
Coronavirus

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try some­thing new as a ‘CEO-part­ner’ at Flag­ship

6 years ago
People

GSK adds to its trove of pos­i­tive da­ta for mul­ti­ple myelo­ma con­tender as ri­vals con­tin­ue to com­mand the spot­light

6 years ago

Dupix­ent clears PhI­II tri­al in new dis­ease as block­buster looks to ex­pand past Re­gen­eron-Sanofi split

6 years ago

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

6 years ago
Bioregnum
Opinion

Be­yond cold stor­age: Tech­nol­o­gy de­signed to keep or­gans warm, helps liv­er trans­plant pa­tients in key study

6 years ago

Al­ny­lam nabs speedy re­view, set­ting up 3rd pos­si­ble ap­proval in 3 years

6 years ago
FDA+

Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

6 years ago
Coronavirus

Piv­otal myas­the­nia gravis da­ta from ar­genx au­gur well for FcRn in­hibitors in de­vel­op­ment

6 years ago

Af­ter de­cou­pling from Re­gen­eron, Sanofi says it’s time to sell the $13B stake picked up in the mar­riage

6 years ago
Deals

An­oth­er NASH de­lay for In­ter­cept frus­trates in­vestors, shares wilt

6 years ago

A new biotech from a long­time de­vel­op­er wants to bring the tar­get­ed can­cer rev­o­lu­tion to the kids left be­hind

6 years ago

Kad­mon kicks off 're­al-time' NDA sub­mis­sion with an­oth­er look at 're­mark­able' chron­ic graft-ver­sus-host-dis­ease da­ta

6 years ago

As CEO bounces back from Covid-19, Apel­lis says FDA meet­ing clears path to file for an OK on Soliris ri­val

6 years ago
FDA+

HotSpot an­nounces $65M Se­ries B, as Nim­bus pi­o­neers look to keep up in a crowd­ing field

6 years ago

Gilead, Gala­pa­gos claim PhI­Ib/III win for fil­go­tinib in ul­cer­a­tive col­i­tis — which pales in com­par­i­son to ri­vals

6 years ago

Covid-19 roundup: Hit with new con­flict ac­cu­sa­tions, Janet Wood­cock steps out of the agen­cy's Covid-19 chain of com­mand

6 years ago
Coronavirus

How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

6 years ago
Coronavirus

With bucks from Pfiz­er added to their new round, Am­plyx steers a tricky course through PhII and a glob­al pan­dem­ic

6 years ago
Financing

GSK sub’s in­jectable out­per­forms Gilead in late-stage PrEP tri­al

6 years ago

Years af­ter Keytru­da, Roche's Tecen­triq monother­a­py wins first-line NSCLC ap­proval. So does it mat­ter?

6 years ago
FDA+

J&J posts a sol­id round of pos­i­tive ear­ly da­ta for their BC­MA/CD3 bis­pe­cif­ic teclis­tam­ab, high­light­ing block­buster ex­pec­ta­tions

6 years ago

As­traZeneca nabs break­through sta­tus, as $7B ADC races to block­buster sta­tus

6 years ago
FDA+

Mod­er­na posts a promis­ing snap­shot of hu­man da­ta for a lead­ing Covid-19 vac­cine — and ral­ly makes Bob Langer a bil­lion­aire

6 years ago
Coronavirus
First page Previous page 200201202203204205206 Next page Last page
A service from the Financial Times